Safety and Pharmacokinetics of Casirivimab and Imdevimab (CAS + IMD) in Pediatric Outpatients With COVID-19

J Pediatric Infect Dis Soc. 2024 Nov 27;13(11):589-593. doi: 10.1093/jpids/piae105.

Abstract

The safety of casirivimab + imdevimab (CAS + IMD) (anti-severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] monoclonal antibodies [mAbs]) in pediatric outpatients with coronavirus disease 2019 (COVID-19) was evaluated in a randomized phase 1/2/3 trial. Consistent with adults, CAS + IMD was generally well tolerated with low drug-induced immunogenicity rates. The findings support the development of next-generation anti-SARS-CoV-2 mAbs for at-risk pediatric patients.

Keywords: COVID-19; monoclonal antibodies; outpatients; pediatrics; treatment.

Publication types

  • Randomized Controlled Trial
  • Clinical Trial, Phase I
  • Clinical Trial, Phase II
  • Clinical Trial, Phase III
  • Multicenter Study

MeSH terms

  • Adolescent
  • Antibodies, Monoclonal / adverse effects
  • Antibodies, Monoclonal / pharmacokinetics
  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized* / adverse effects
  • Antibodies, Monoclonal, Humanized* / pharmacokinetics
  • Antibodies, Monoclonal, Humanized* / therapeutic use
  • Antibodies, Neutralizing
  • Antiviral Agents / adverse effects
  • Antiviral Agents / pharmacokinetics
  • Antiviral Agents / therapeutic use
  • COVID-19 / immunology
  • COVID-19 Drug Treatment*
  • Child
  • Child, Preschool
  • Drug Combinations
  • Female
  • Humans
  • Male
  • Outpatients
  • SARS-CoV-2* / immunology

Substances

  • Antibodies, Monoclonal, Humanized
  • casirivimab and imdevimab drug combination
  • Antiviral Agents
  • Drug Combinations
  • casirivimab
  • Antibodies, Monoclonal
  • Antibodies, Neutralizing